SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

PRNewswire/ -- (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited ...